Lin X, et al. - Using UALCAN and the Human Protein Atlas, researchers assessed the prognostic usefulness of TMED2 in patients with breast cancer. They performed comparisons between breast cancer and normal breast tissue, with respect to TMED2 expression level and DNA methylation. In breast cancer sample and normal breast tissue, the copy number of TMED2 was examined with Oncomine. In all breast cancers and in different intrinsic subtypes, the prognostic importance of TMED2 mRNA expression was determined by using the Kaplan–Meier Plotter database. According to findings, a significant association of higher expression of TMED2 with unfavorable outcomes was observed in patients with breast cancer. Therefore, the oncogenic nature of TMED2, as well as its value as a potential target for breast cancer therapy, was suggested.